Genome-wide lentiviral shRNA screen identifies serine/arginine-rich splicing factor 2 as a determinant of oncolytic virus activity in breast cancer cells

Oncolytic human herpes simplex virus type 1 (HSV-1) shows promising treatment efficacy in late-stage clinical trials. The anticancer activity of oncolytic viruses relies on deregulated pathways in cancer cells, which make them permissive to oncolysis. To identify pathways that restrict HSV-1 KM100-m...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Oncogene 2016-05, Vol.35 (19), p.2465-2474
Hauptverfasser:	Workenhe, S T, Ketela, T, Moffat, J, Cuddington, B P, Mossman, K L
Format:	Artikel
Sprache:	eng
Schlagworte:	631/67/1347 64/60 82/80 96/106 96/2 Alternative splicing Antitumor activity Apoptosis Apoptosis - drug effects Apoptosis - genetics Arginine Breast cancer Breast Neoplasms - pathology Camptothecin - analogs & derivatives Camptothecin - pharmacology Cell Biology Cell Line, Tumor Clinical trials Cytotoxicity Development and progression DNA biosynthesis DNA topoisomerase DNA viruses Gene Knockout Techniques Genetic aspects Genomes Genomics Health aspects Herpes simplex Herpes simplex virus Herpes simplex virus 1 Herpes viruses Herpesvirus 1, Human - physiology Human Genetics Humans Internal Medicine Lentivirus - genetics Medicine Medicine & Public Health mRNA Oncology Oncolysis Oncolytic Virotherapy original-article Phosphoproteins Phosphorylation Phosphorylation - drug effects Phosphorylation - genetics RNA, Small Interfering - genetics Rodents Serine Serine-Arginine Splicing Factors - deficiency Serine-Arginine Splicing Factors - genetics Serine-Arginine Splicing Factors - metabolism Spliceosomes Splicing factors Tumors Virology Virus Replication - drug effects Virus Replication - genetics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!